Alliance Pharma PLC has disclosed its total voting rights in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1. As of 29 February 2024, the company's issued share capital consists of 540,395,049 Ordinary Shares of 1p each, resulting in the total number of voting rights in the company being 540,395,049. Shareholders can use this figure as the denominator for the calculations to determine if they are required to notify their interest in the company under the FCA's Disclosure Guidance and Transparency Rules.

Alliance Pharma PLC, listed on AIM, is an international healthcare group focused on consumer healthcare. The company's purpose is to empower people to make a positive difference to their health and wellbeing by making trusted and proven brands available worldwide. The company aims for organic growth by investing in priority brands and channels, related innovation, and selective geographic expansion to increase the reach of its brands. Additionally, the company may consider enhancing its organic growth through selective, complementary acquisitions.

For further information, investors can contact Alliance Pharma PLC through the provided contact details. Alliance Pharma's Head of Investor Relations, Cora McCallum, can be reached at +44 (0)1249 705168 or [email protected]. Additionally, Buchanan can be contacted at +44 (0)20 7466 5000 or [email protected], while Deutsche Numis and Investec Bank plc are also available for inquiries.

This announcement provides shareholders and the market with transparency regarding Alliance Pharma PLC's total voting rights and its strategic focus on empowering individuals to improve their health and wellbeing through the availability of trusted and proven healthcare brands.